Mosquirix RTS,S/AS01 Malaria Vaccine Description
Mosquirix RTS, S/AS01 is a recombinant vaccine candidate consisting of the P. falciparum circumsporozoite protein (CSP) from the pre-erythrocytic stage. Mosquirix aims to trigger the immune system to defend against the first stages when the Plasmodium falciparum malaria parasite enters the human host’s bloodstream through a mosquito bite and infects liver cells.
The T-cell epitope of CSP is O-fucosylated in Plasmodium falciparum and Plasmodium vivax, while the RTS,S vaccine produced in yeast is not.
Mosquirix does not provide complete protection against malaria caused by P. falciparum.
The vaccine is designed to prevent the parasite from infecting the liver, mature, multiply, re-enter the bloodstream, and infect red blood cells, leading to disease symptoms.
GlaxoSmithKline Biologicals S.A. Mosquirix H-W-2300.
Mosquirix RTS,S/AS01 Malaria Vaccine History
The RTS,S/AS01E malaria vaccine, developed by GSK for more than 30 years and in partnership with PATH since 2001, is currently being piloted in regions of Ghana, Kenya, and Malawi under the Malaria Vaccine Implementation Programme (MVIP). Ministries of health are leading the implementation of the vaccine, which is being given to young children through the three countries’ routine immunization programs, with WHO providing technical and scientific leadership, playing a coordinating role, and working in collaboration with GSK, PATH, and a range of other partners.
To date, RTS,S/AS01E is the first malaria vaccine to have received a positive review by regulatory authorities (positive scientific opinion from the European Medicines Agency and approval by the regulatory authorities of Ghana, Kenya, and Malawi for use in the MVIP. The first dose of the vaccine has reached more than 500,000 children since ministries of health initiated the three participating countries' pilots in 2019.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information, please visit GSK.
Bharat Biotech (BBIL) is a pioneering, innovative biotechnology company known for its world-class research and development and manufacturing capabilities and its commitment to delivering safe, affordable, and high-quality vaccines bio-therapeutics against infectious diseases.
Mosquirix RTS,S/AS01 Malaria Vaccine Indication
Mosquirix (RTS,S/AS01) has been developed to prevent malaria in young children living in malaria-endemic regions.
Mosquirix is currently indicated for children aged 5 to 17 months and infants aged 6 to 12 weeks at the first vaccination time to help protect against malaria caused by the parasite Plasmodium falciparum.
Mosquirix is not approved for older children, teens, nor adults.
Mosquirix RTS,S/AS01 Malaria Vaccine Dosage
Mosquirix is administered as an intramuscular injection.
The vaccine should only be used in areas of the world where malaria caused by Plasmodium falciparum is prevalent, and according to official recommendations in those areas.
Mosquirix RTS,S/AS01 Malaria Vaccine News
March 17, 2021 - Study: Adverse pregnancy outcomes among women presenting at antenatal clinics in Ouélessébougou, Mali. Conclusion: Low gravidity and young age predict perinatal death and PTD. The information collected here can be used as a baseline for adverse pregnancy outcomes in future vaccine trials in pregnant women.
March 12, 2021 - Review: Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?
March 1, 2021 - The U.S. CDC reported a malaria epidemic is ongoing in Burundi. Since January 1, 2019, the Ministry of Health has reported nearly 6 million cases (out of a total population of approximately 12 million), with more than 1,800 deaths.
February 25, 2021 - The WHO reported El Salvador today became the first country in Central America to be awarded a certification of malaria elimination by the World Health Organization. The certification follows more than 50 years of commitment by the Salvadoran government and people to ending the disease in a country with a dense population and geography hospitable to malaria.
January 27, 2021 - GSK, PATH, and Bharat Biotech (BBIL) announced a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine, and a license on all rights of the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the adjuvant's production (AS01E) and will supply it to BBIL.
January 27, 2021 - Fighting malaria in the lab and on the ground. Malaria is one of the world’s oldest diseases, with evidence of the mosquito-borne illness found in tissues from Ancient Egyptian mummies1. But despite its long history and our understanding of its biology, malaria remains one of the world’s deadliest diseases.
September 8, 2020 - The Nature journal published: The quest for a vaccine against malaria.
August 16, 2019 - Overcoming obstacles to end malaria. Currently, the only treatment available for this type of malaria, primaquine, needs to be taken for fourteen days so is often associated with poor compliance. To address this and make it easier for patients, we have been developing tafenoquine, in partnership with the not-for-profit foundation Medicines for Malaria Venture (MMV), as a single-dose treatment.
July 19, 2019 - The Lancet published an article: RTS,S malaria vaccine could provide major public health benefits.
Mosquirix RTS,S/AS01 Malaria Vaccine Clinical Trials
Clinical Trial NCT03806465: An Evaluation of the Cluster-randomised Pilot Implementation of RTS,S/AS01 Through Routine Health Systems in Moderate to High Malaria Transmission Settings in Africa. Last Update Posted: November 17, 2020.